Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit

Endocrine Practice

Volumn 19, Issue 1, 2013, Pages 81-90

  Abuannadi, Mohammad ^a   Kosiborod, Mikhail ^a   Riggs, Lisa ^a   House, John A ^a   Hamburg, Mitchell S ^a   Kennedy, Kevin F ^a   Marso, Steven P ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; ONDANSETRON; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; INSULIN; PEPTIDE; VENOM;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIAC INTENSIVE CARE UNIT; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUSHING; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INSULIN INFUSION; INTENSIVE CARE UNIT; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PILOT STUDY; PROSPECTIVE STUDY; SIDE EFFECT; STEADY STATE; VOMITING; FEASIBILITY STUDY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PEPTIDES; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOMS;

EID: 84881507609     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12196.OR     Document Type: Article

References (43)

1. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003;78: 1471-1478. (Pubitemid 37475630)
2. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773-778. (Pubitemid 30128815)
3. Pomposelli JJ, Baxter JK, 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr. 1998;22:77-81. (Pubitemid 28117569)
4. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-982. (Pubitemid 36121050)
5. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation. 2008;117:1018-1027.
6. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: Implications for patients with and without recognized diabetes. Circulation. 2005;111:3078-3086. (Pubitemid 40847785)
7. Van den Berghe G, Wilmer A, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461. (Pubitemid 43200296)
8. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
9. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-1297.
10. Van den Berghe G, Schetz M, Vlasselaers D, et al. Clinical review: Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? J Clin Endocrinol Metab. 2009;94:3163-3170.
11. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32: 1119-1131.
12. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27:553-591. (Pubitemid 38174086)
13. Aragon D. Evaluation of nursing work effort and perceptions about blood glucose testing in tight glycemic control. Am J Crit Care. 2006;15:370-377. (Pubitemid 44859176)
14. Gentilella R, Bianchi C, Rossi A, Rotella CM. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab. 2009;11:544-556.
15. Kosiborod M, Inzucchi S, Hamburg M, et al. Feasibility, effectiveness and safety of intensive glucose control in critically ill hyperglycemic patients hospitalized with acute coronary syndromes. Circulation. 2007;116:3529:II-3799.
16. Goldberg PA, Roussel MG, Inzucchi SE. Clinical results of an updated insulin infusion protocol in critically ill patients. Diabetes Spectrum. 2005;18:188-191. (Pubitemid 41665894)
17. Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology. 2006;105:244-252. (Pubitemid 44148168)
18. Eslami S, Taherzadeh Z, Schultz MJ, Abu-Hanna A. Glucose variability measures and their effect on mortality: a systematic review. Intensive Care Med. 2011;37:583-593.
19. Wintergerst KA, Buckingham B, Gandrud L, Wong BJ, Kache S, Wilson DM. Association of hypoglycemia, hyperglycemia, and glucose variability with morbidity and death in the pediatric intensive care unit. Pediatrics. 2006;118:173-179. (Pubitemid 46071160)
20. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111:3078-3086. (Pubitemid 40847785)
21. Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: A randomised double-blind placebo-controlled cross over study. Crit Care. 2009;13:R67.
22. Deane AM, Chapman MJ, Fraser RJ, et al. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med. 2010;38:1261-1269.
23. Deane AM, Summers MJ, Zaknic AV, et al. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care. 2011;15:R35.
24. Meier JJ, Weyhe D, Michaely M, et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med. 2004;32:848-851. (Pubitemid 38340086)
25. Pinelli NR, Jones MC, Monday LM, Smith Z, Rhoney DH. Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients. Ann Pharmacother. 2012;46:124-129.
26. Dossett LA, Cao H, Mowery NT, Dortch MJ, Morris JM Jr., May AK. Blood glucose variability is associated with mortality in the surgical intensive care unit. Am Surg. 2008;74:679-685.
27. Ali NA, O'Brien JM Jr., Dungan K, et al. Glucose variability and mortality in patients with sepsis. Crit Care Med. 2008;36:2316-2321.
28. McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B. Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine. Diabetes Technol Ther. 2009;11:339-344.
29. Lipska KJ, Venkitachalam L, Gosch K, et al. Glucose variability and mortality in patients hospitalized with acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2012;5:550-557.
30. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635. (Pubitemid 39441462)
31. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on gly cemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28:1092-1100. (Pubitemid 40616618)
32. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA. 2009;301:1556-1564.
33. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 2009;35: 1738-1748.
34. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26: 1485-1489. (Pubitemid 36929183)
35. O'Keefe JH, Abuannadi M, Lavie CJ, Bell DS. Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2011;86:128-138.
36. Hutton RA, Mikhailidis D, Dormandy KM, Ginsburg J. Platelet aggregation studies during transient hypoglycaemia: a potential method for evaluating platelet function. J Clin Pathol. 1979;32:434-438. (Pubitemid 9207986)
37. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005;26:1255-1261. (Pubitemid 41435454)
38. Sokos GG, Bolukoglu H, German J, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824-829. (Pubitemid 47268274)
39. Mussig K, Oncu A, Lindauer P, et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol. 2008;102:646-647.
40. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965. (Pubitemid 38282847)
41. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694-699. (Pubitemid 44881367)
42. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491-1499.
43. Nathanson D, Ullman B, Löfstrom U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: A double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55:926-935.